Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis

Overview

Journal Int J Angiol

Date 2017 Nov 17

PMID 29142486

Authors

S M Shafiee

F Noorabad-Ghahroodi

A Amirfarhangi

S R Hosseini-Fard

Z Sharifi

M Najafi

Affiliations

Soon will be listed here.

Abstract

Neointimal hyperplasia is known as a main factor contributing to in-stent restenosis (ISR). Monocytes may play a central role in vessel restenosis process after stent implantation. The aim of this study was to investigate the relationships between the urokinase-type plasminogen activator (PLAU) and vitronectin (Vtn) gene expression levels in peripheral blood mononuclear cell samples isolated from whole blood of 66 patients undergoing coronary artery angiography (22 controls, stenosis < 0.05%; 22 with stent no-restenosis and stenosis < 70%; and 22 with ISR and stenosis > 70%). The Vtn and PLAU gene expression levels were measured by real-time quantitative polymerase chain reaction technique. The age- and gender-independent increases in the expression levels of Vtn (17-fold; < 0.001) and PLAU (27-fold; < 0.0001) genes were found in the patients with ISR as compared with the control group. The results suggested that the Vtn and PLAU genes may be involved in the coronary artery ISR.

References

Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo I . Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res. 2002; 90(11):1167-72. DOI: 10.1161/01.res.0000020561.03244.7e. View

Noorabad-Ghahroodi F, Abdi S, Zand A, Najafi M . HGDB: A web retrieving cardiovascular-associated gene data. Int J Cardiol. 2017; 232:117-120. DOI: 10.1016/j.ijcard.2017.01.043. View

Hoffmann R, Mintz G . Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J. 2000; 21(21):1739-49. DOI: 10.1053/euhj.2000.2153. View

Baldwin J, Sood V, Elfline M, Luke C, Dewyer N, Diaz J . The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg. 2012; 56(4):1089-97. PMC: 3463752. DOI: 10.1016/j.jvs.2012.02.054. View

Cao D, Guo Y, Colman R . Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res. 2004; 94(9):1227-34. DOI: 10.1161/01.RES.0000126567.75232.46. View

Fuhrman B . The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2011; 222(1):8-14. DOI: 10.1016/j.atherosclerosis.2011.10.044. View

Fleetwood A, Achuthan A, Schultz H, Nansen A, Almholt K, Usher P . Urokinase plasminogen activator is a central regulator of macrophage three-dimensional invasion, matrix degradation, and adhesion. J Immunol. 2014; 192(8):3540-7. DOI: 10.4049/jimmunol.1302864. View

Fischman D, Leon M, Baim D, Schatz R, Savage M, Penn I . A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331(8):496-501. DOI: 10.1056/NEJM199408253310802. View

Indolfi C, Pavia M, Angelillo I . Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol. 2005; 95(10):1146-52. DOI: 10.1016/j.amjcard.2005.01.040. View

10.

Wang Y, Liu L, He Z, Ding K, Xue F . Phenotypic transformation and migration of adventitial cells following angioplasty. Exp Ther Med. 2012; 4(1):26-32. PMC: 3460273. DOI: 10.3892/etm.2012.551. View

11.

Yang Z, Shen Y, Hu J, Zhang Q, Ding F, Zhang R . Impact of coronary collateral circulation on angiographic in-stent restenosis in patients with stable coronary artery disease and chronic total occlusion. Int J Cardiol. 2016; 227:485-489. DOI: 10.1016/j.ijcard.2016.10.117. View

12.

Thorpe P . Identification and Treatment of Restenosis in Failing Venous Stents: The Role of Intravascular Ultrasound. J Vasc Surg Venous Lymphat Disord. 2016; 2(1):109-10. DOI: 10.1016/j.jvsv.2013.10.020. View

13.

Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J . Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol. 2004; 43(1):18-23. DOI: 10.1016/j.jacc.2003.08.026. View

14.

De Lorenzi V, Sarra Ferraris G, Madsen J, Lupia M, Andreasen P, Sidenius N . Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin. EMBO Rep. 2016; 17(7):982-98. PMC: 4931562. DOI: 10.15252/embr.201541681. View

15.

Schousboe S, Egelund R, Kirkegaard T, Preissner K, Rodenburg K, Andreasen P . Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F. Thromb Haemost. 2000; 83(5):742-51. View

16.

Schafer K, Schroeter M, Dellas C, Puls M, Nitsche M, Weiss E . Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol. 2006; 26(6):1254-9. DOI: 10.1161/01.ATV.0000215982.14003.b7. View

17.

Hong Y, Jeong M, Ahn Y, Mintz G, Kim S, Lee S . Incidence, predictors, and clinical impact of tissue prolapse after stent implantation for saphenous vein graft disease: intravascular ultrasound study. Int J Cardiol. 2013; 168(3):3073-5. DOI: 10.1016/j.ijcard.2013.04.090. View

18.

Ge J, Shen C, Liang C, Chen L, Qian J, Chen H . Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. Int J Cardiol. 2005; 112(1):85-90. DOI: 10.1016/j.ijcard.2005.10.016. View

19.

Ekmekci O, Ekmekci H . Vitronectin in atherosclerotic disease. Clin Chim Acta. 2006; 368(1-2):77-83. DOI: 10.1016/j.cca.2005.12.015. View

20.

Hillig T, Engelholm L, Ingvarsen S, Madsen D, Gardsvoll H, Larsen J . A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem. 2008; 283(22):15217-23. PMC: 3258879. DOI: 10.1074/jbc.C700214200. View